Inflammation, lipids, and pain in vulvar disease

Megan L. Falsetta a,b,⁎, Krishna Rao Maddipati c,d, Kenneth V. Honn c,d

a University of Rochester, OB/GYN Research Division, Rochester, NY, United States of America
b University of Rochester, Pharmacology and Physiology Department, Rochester, NY, United States of America
c Wayne State University, Pathology Department, Detroit, MI, United States of America
d Wayne State University, Lipidomics Core Facility and Bioactive Lipids Research Program, Detroit, MI, United States of America

Abstract

Localized provoked vulvodynia (LPV) affects ~14 million people in the US (9% of women), destroying lives and relationships. LPV is characterized by chronic pain (>3 months) upon touch to the vestibule, which surrounds the vaginal opening. Many patients go months or years without a diagnosis. Once diagnosed, the treatments available only manage the symptoms of disease and do not correct the underlying problem. We have focused on elucidating the underlying mechanisms of chronic vulvar pain to speed diagnosis and improve intervention and management. We determined the inflammatory response to microorganisms, even members of the resident microflora, sets off a chain of events that culminates in chronic pain. This agrees with findings from several other groups, which show inflammation is altered in the painful vestibule. The vestibule of patients is acutely sensitive to inflammatory stimuli to the point of being deleterious. Rather than protect against vaginal infection, it causes heightened inflammation that does not resolve, which coincides with alterations in lipid metabolism that favor production of proinflammatory lipids and not pro-resolving lipids. Lipid dysbiosis in turn triggers pain signaling through the transient receptor potential vanilloid subtype 4 receptor (TRPV4). Treatment with specialized pro-resolving mediators (SPMs) that foster resolution reduces inflammation in fibroblasts and mice and vulvar sensitivity in mice. SPMs, specifically maresin 1, act on more than one part of the vulvodynia mechanism by limiting inflammation and acutely inhibiting TRPV4 signaling. Therefore, SPMs or other agents that target inflammation and/or TRPV4 signaling could prove effective as new vulvodynia therapies.

© 2023 Elsevier Inc. All rights reserved.

Keywords:
Pain
Vulvodynia
SPMs
Lipids
TRPV4
Fibroblasts
Inflammation

Contents

1. Vulvar pain ................................................ 2
2. Connections between inflammation and vulvar pain ..................................... 3
3. Lipid dysbiosis and vulvar pain .......................................................... 5
4. Neuro-inflammatory mechanisms of vulvar pain ....................................... 6
5. Conclusion ................................................ 8
6. Current knowledge gaps and future directions ......................................... 8
Declaration of Competing Interest ................................................................. 8
Acknowledgments ................................................................. 8
References ................................................................. 8

Abbreviations: 4αPDD, 4alpha-Phorbol 12,13-didecanoate; ADP, adenosine diphosphate; COX-2, cyclooxygenase-2; CYP450, cytochrome peroxidase 450; DHA, docosahexanoic acid; DHET, dihydroxyeicosatrienoic acid; DMSO, dimethyl sulfoxide; EET, eicosatrienoic acid; GPCR, G-coupled protein receptor; HDHA, docosahexaenoic acid; HETE, hydroxyeicosatetraenoic acid; IL-1β, interleukin-1 beta; IL-6, interleukin-6; LPV, localized provoked vulvodynia; PAMP, pathogen associated molecular pattern; PGE2, prostaglandin E2; PRR, pathogen recognition receptor; NIH, National Institutes of Health; NSAIDs, non-steroidal anti-inflammatory drugs; NFκB, nuclear factor kappa B; sEH, soluble epoxide hydrolase; SNPs, small nucleotide polymorphisms; SNR, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TLR-3, toll-like receptor 3; TRPV4, transient receptor potential vanilloid subtype 4 receptor.

⁎ Corresponding author at: Obstetrics and Gynecology, Pharmacology and Physiology, 601 Elmwood Ave, Box 668, Rochester, NY 14642, United States of America.

E-mail address: Megan_Falsetta@URMC.Rochester.edu (M.L. Falsetta).

https://doi.org/10.1016/j.pharmthera.2023.108467
0163-7258/© 2023 Elsevier Inc. All rights reserved.
1. Vulvar pain

Everyone with a vulva is likely to experience pain or discomfort in this area at some point in their life, even if only transiently, such as during pregnancy, after childbirth, or during menopause (Danby & Margesson, 2010; Simonelli, Eleuteri, Petruccielli, & Rossi, 2014). Despite the ubiquity of vulvar pain, our fundamental understanding of the mechanisms involved are limited, and epidemiological studies indicate it is both underdiagnosed and seldom discussed (Andrews, 2011; Bohm-Starke, 2010; Bornstein et al., 2016; Damsted-Petersen, Boyer, & Pukall, 2009; Dargie, Holden, & Pukall, 2017; Donders & Bellen, 2012; Eppsteiner, Boardman, & Stockdale, 2014; Falsetta et al., 2015; Falsetta et al., 2018; Falsetta et al., 2021; Falsetta, Foster, Bonham, & Phipps, 2017; Farmer et al., 2011; Foster et al., 2015; Grovers, 2010; Harlow et al., 2017; NIH, 2016; Pukall et al., 2016; Reed et al., 2012; Reed et al., 2014; Rosen, Dawson, Brooks, & Kellogg-Spadt, 2019; Stockdale & Lawson, 2014; Wesselmann, Bonham, & Foster, 2014; Wylie, 2017; Zanotta et al., 2018). Since the year 2000, fewer than 200 NIH grants have been funded on “vulvar pain,” which includes projects focused on endometriosis and pelvic pain (Vulvar Pain [Internet] 2000–2023).

Patients with vulvar pain or sexual dysfunction often do not vocalize these concerns to their medical providers (Parish & Clayton, 2007; Bohm-Starke, 2010; Bornstein et al., 2016; Damsted-Petersen, Boyer, & Pukall, 2009; Dargie, Holden, & Pukall, 2017; Donders & Bellen, 2012; Eppsteiner, Boardman, & Stockdale, 2014; Falsetta et al., 2015; Falsetta et al., 2018; Falsetta et al., 2021; Falsetta, Foster, Bonham, & Phipps, 2017; Farmer et al., 2011; Foster et al., 2015; Grovers, 2010; Harlow et al., 2017; NIH, 2016; Pukall et al., 2016; Reed et al., 2012; Reed et al., 2014; Rosen, Dawson, Brooks, & Kellogg-Spadt, 2019; Stockdale & Lawson, 2014; Wesselmann, Bonham, & Foster, 2014; Wylie, 2017; Zanotta et al., 2018). Epidemiological studies show patients perceive their provider is not equipped to discuss topics pertaining to sexual health and many fear judgement or embarrassment (Kingsberg et al., 2019). Patient perception may reflect a limited focus on sexual medicine training in many medical school curricula (Kingsberg et al., 2019; Parish & Clayton, 2007; Rubin et al., 2018; Shindel & Parish, 2013; Solursh et al., 2003). Most patients look for providers to initiate the conversation. When these conversations do not take place, patient needs go unmet.

Yet, vulvar pain remains a common and complex problem (Harlow et al., 2014; Harlow & Stewart, 2003; Nguyen, Turner, Rydell, Maclehole, & Harlow, 2013; Reed, et al., 2012; Reed et al., 2014; Reed, Harlow, Sen, Legocki, et al., 2012). It can be acute and may resolve with time or treatment, or it can be chronic (Haefner et al., 2005; Sadownik, 2014; Stockdale & Lawson, 2014). Vulvodynia is the most common cause of chronic dyspareunia (painful intercourse), affecting anywhere from 8 to 12% of women in the United States (Harlow et al., 2014; Harlow & Stewart, 2003; Reed, Harlow, Sen, Legocki, et al., 2012). Lifetime risk has been estimated even higher, suggesting that up to a third of persons with vulvas could be affected (Groysman, 2010). If a patient has chronic vulvar pain that does not resolve for at least 3 months and cannot be explained by any other cause, they usually receive a vulvodynia diagnosis (Haefner et al., 2005; Stockdale & Lawson, 2014). Vulvodynia can develop at any age and affects a large portion of reproductive age individuals. Vulvodynia destroys the patient’s quality of life and has a negative impact on their relationships; it can make it difficult to sit, wear pants, ride a bicycle, use a tampon or menstrual cup, or engage in sexual activity (Haefner et al., 2005; Jeon et al., 2013; Kingdon, 2009; NIH, 2016; Nunns et al., 2010; Pukall et al., 2016; Reed, Harlow, Sen, Edwards, et al., 2012; Sadownik, 2014; Stenson, 2017; Stockdale & Lawson, 2014; Wesselmann et al., 2014). Because vulvodynia is a diagnosis of exclusion, patients suffer months to years before a diagnosis. Once diagnosed, treatment is often “trial and error,” escalating from less to more invasive and often culminating in surgical procedures to remove the affected tissue, essentially amputating a portion of the vulva.

The most common type of vulvodynia is localized provoked vulvodynia (Akopians & Rapkin, 2015; Bohm-Starke, 2010; Falsetta et al., 2015; Falsetta et al., 2018; Falsetta et al., 2021). This is pain that occurs upon touch (mechanical allodynia) and is localized to the vulvar vestibule, or ring of tissue surrounding the vaginal opening. Adjacent areas are non-painful to touch, while the vestibule is extremely sensitive, particularly between the 5 and 7-o’clock positions (Fig. 1). Removal of this tissue during a surgical procedure termed a vestibulectomy is often curative and carries over a 90% satisfaction rate (Andrews, 2011; Rosen et al., 2019; Stenson, 2017; Tommola, Unkila-Kallio, & Paavonen, 2010; Tommola, Unkila-Kallio, & Paavonen, 2011; Tommola, Unkila-Kallio, & Paavonen, 2012; Wu, Goldstein, Klenfann, & Moawad, 2019). However, due to its invasive nature and inherent risk, vestibulectomy is often delayed until all other treatments fail.

Treatment for vulvodynia is trial and error (Danby & Margesson, 2010; Eppsteiner et al., 2014; Falsetta et al., 2017; Fischer, 2004; Haefner et al., 2005; Kingdon, 2009; Nunns et al., 2010; Rosen et al., 2019; Sadownik, 2014; Spoelstra, Dijkstra, van Driel, & Weijmar Schultz, 2011; Stenson, 2017; Stockdale & Lawson, 2014; Tieu & MacGregor, 2011; Tommola et al., 2010; Wesselmann et al., 2014; Wu et al., 2019), usually beginning with conservative management, including use of hypoallergenic soaps and lotions, wearing exclusively cotton undergarments, and avoiding wearing tight clothing or causing friction to the affected area. Most patients then move onto topical therapies, such as lidocaine, which is applied to the area before inserting anything into the vagina. This can be helpful, but it only temporarily reduces sensation in the area and can be transferred to the partner during intercourse. Gabapentin, selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitor (SNRIs) are the next line, sometimes applied topically or injected, but typically dosed orally. Patients may try botulinum toxin injection into the area, which is thought to act on substance P to reduce pain. Patients also engage in cognitive behavioral therapy, bio-feedback, mediation and mindfulness, and relationship, psychiatric, or sexual counseling. When these fail, eligible patients usually elect vestibulectomy.

Vulvodynia can be further sub-divided into categories based on clinical presentation, but little to no mechanistic, scientific, or biological evidence is available to distinguish these categories (Bornstein et al., 2016; Eppsteiner et al., 2014; Falsetta et al., 2017; Haefner et al., 2005; Stockdale & Lawson, 2014). Patients may have generalized vulvodynia, where the entire vulva is affected, making them ineligible for surgery. Patients can also have unprovoked or spontaneous pain. Patients can have primary or secondary vulvodynia, referring to whether they experienced a pain-free intercourse period before developing pain (secondary) or whether pain was experienced at the first attempt at tampon use or intercourse (primary). Because there is limited scientific information, it is difficult to discern if these presentations are manifestations of the same disease or unique disease entities. Clearly, there are knowledge gaps, leading to treatment delays and failures and an overall poor quality of life in vulvodynia patients. Although there is some evidence to support the use of any approved vulvodynia therapy, there is no level...
1 evidence for their use, meaning most treatments have not been demonstrated more effective in blinded randomized control trials. More recently, our group and others have begun to unravel the biological mechanisms at play in vulvodynia with a focus on developing more effective mechanism-based therapies through the use of cellular and mouse models of disease (Akopians & Rapkin, 2015; Baker, Peresleni, & Kocis, 2016; Barry, Matusica, & Haberberger, 2019; Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018; Foster et al., 2007; Foster et al., 2015; Leclair et al., 2011; Leclair, Leeborg, Jacobson-Dunlop, Goetsch, & Morgan, 2014; Reed et al., 2018; Tommola et al., 2016; Tommola, Butzow, Unkila-Kallio, Paavonen, & Meri, 2015; Zanotta et al., 2018).

2. Connections between inflammation and vulvar pain

2.1. Yeast infections and vulvodynia

In patients with secondary vulvodynia, which appears more common than primary vulvodynia, there is a tipping point where patients go from pain-free to painful intercourse (Bornstein et al., 2016; Falsetta et al., 2017; Fischer, 2004; Haefner et al., 2005; Stockdale & Lawson, 2014). The most common warning sign is the occurrence of transient bouts of pain immediately following intercourse. It is difficult to discern a clear environmental cause for vulvodynia, as patients recall numerous factors that could have precipitated their pain, including sexual assault, vulvovaginal infections, childbirth, injury, abuse, trauma, and more (Arnold, Bachmann, Rosen, Kelly, & Rhoads, 2006; Reed et al., 2014; Reed, Harlow,Sen, Edwards, et al., 2012; Reed, Harlow, Sen, Legocki, et al., 2012). However, the most common precipitating factor cited by >70% of patients is a previous history of chronic or recurrent yeast infection (Donders & Bellen, 2012). Patients recall experiencing a yeast infection that never fully cleared or 4 or more yeast infections in the past year. It is important to note that the majority of yeast infections are self-diagnosed and treated with over-the-counter antifungals (Hani, Shivakumar, Vaghefi, Osmani, & Shrivastava, 2015; Lipsky & Taylor, 1996; Mendling et al., 2012). Few patients undergo laboratory testing. Therefore, it is possible that other agents, such as bacteria, viruses, or irritants could play a role.

There is strong evidence from patients, human cells, and animal studies to implicate yeast, especially Candida albicans, in the onset of vulvodynia. C. albicans is among the most common agents that cause vulvovaginal yeast infection (Farmer et al., 2011; Giraldo et al., 2000; Peters et al., 2014). Other non-albicans Candida, such as C. glabrata and C. tropicalis come in close second. Patients with vulvodynia can show cutaneous hypersensitivity to C. albicans, similar to an allergic reaction, suggestive of an overall sensitivity to this yeast species (Ramirez De Knott et al., 2005). Human fibroblasts taken from painful areas of the vestibule of localized provoked vulvodynia (LPV) patients also show a hypersensitivity to yeast, where <100 yeast cells elicit an inflammatory response characterized by elevated levels of interleukin-6 (IL-6) and prostaglandin E₂ (PGE₂) (Falsetta et al., 2015). Patients with vulvodynia do not have active yeast infections at the time of diagnosis (Haefner et al., 2005; Stockdale & Lawson, 2014); this data provides evidence that a small number of yeast, which are beneath the clinical limit of detection, can cause a significant inflammatory response in painful areas of the vestibule. This response is specific to the painful area of the vestibule and does not occur in cells taken from an adjacent non-painful site in the external vulva, which require numbers of yeast commiserate with an active infection to elicit a response (Falsetta et al., 2015). Fibroblasts from the painful vestibule also show enhanced sensitivity to C. glabrata, C. tropicalis, Saccharomyces cerevisiae, and zymosan, a yeast cell wall extract from Saccharomyces, compared to non-painful sites in the patient and from the same anatomical sites in patients without vulvodynia (Foster et al., 2015). Furthermore, repeated vulvovaginal infection with C. albicans or injection of zymosan into the vulva of several mouse strains (e.g. CD-1, BALB/c, and C57/BL-6) results in persistent sensitivity to touch (up to 16 weeks), while animals receiving saline remain insensitive (Falsetta et al., 2021; Farmer et al., 2011).

2.2. Inflammation and vulvar fibroblasts

We developed a fibroblast model for studying vulvodynia where each patient serves as their own control by taking 6 mm biopsies from both the painful vestibule and external non-painful vulva (Fig. 2). Biopsies are collected during a scheduled vestibulectomy for LPV patients and during another gynecologic surgery in patients without a history of vulvar disease (controls), which minimizes patient discomfort and infection risk. Each biopsy tissue can then be partitioned into up to 3 individual pieces for development of primary fibroblast lines and other approaches, such as histology, proteomics, transcriptomics, and lipidomics (Fig. 2). This design facilitates paired analysis and allows for the comparison of painful to non-painful areas in both cases and controls to pinpoint what is happening at the painful vulvar vestibule. The high satisfaction rate with vestibulectomy (Tommola et al., 2010; Tommola et al., 2011; Tommola et al., 2012) supports the hypothesis that there is something unique about the vestibule that can lead to chronic pain.

Pursuant to the possible connection between vulvovaginal yeast infection and vulvodynia, we introduced live yeast infection into our model and found that fibroblasts from the painful vestibule are indeed more sensitive to yeast than non-painful areas from cases and controls, measured by IL-6 and PGE₂ production (Falsetta et al., 2015; Foster et al., 2015). Furthermore, we determined the response of fibroblasts to C. albicans could predict the patient threshold at the site from which the fibroblasts were obtained (Foster et al., 2015). This finding 1 implicates inflammation in the vulvodynia mechanism, 2 demonstrates that the model correlates with key patient measures, and 3) establishes IL-6 and PGE₂ as surrogate measures of pain, facilitating high-throughput mechanistic studies that are impossible to conduct in the patient.

We considered the mechanisms by which fibroblasts might recognize yeast, focusing on recognition of conserved pathogen-associated molecular patterns (PAMPs) by host pattern recognition receptors (PRRs). Based on the chronicity of pain, we initially focused on PRRs involved in recognizing β-glucan, a key component of the C. albicans biofilm matrix associated with chronic infection (Alves et al., 2014; Chaffin, 2008; Harriott, Lilly, Rodriguez, Fidel Jr., & Noverr, 2010; Nett, Sanchez, Cain, & Andes, 2010; Taff et al., 2012). We later expanded our scope to toll-like receptors (Falsetta et al., 2018), which can recognize specific components of the yeast cell, as well as bacteria and viruses (Bourgeois & Kuchler, 2012; Doyle & O’Neill, 2006; Gow, van de Veerdonk, Brown, & Netea, 2012). We also looked at bradykinin receptors (Falsetta et al., 2016), which are not PRRs, but are involved in pain signaling. All the receptors studied were determined to be significantly more highly expressed in the painful vestibule compared to non-painful sites, likely accounting for enhanced sensitivity to C. albicans (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018; Falsetta et al., 2021).

We found that sensitivity to inflammatory stimuli was also elevated in the vestibule of patients without vulvodynia albeit to much lesser extent (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018; Falsetta et al., 2021). These findings suggest that pain in the vestibule may be an extreme of a normally protective response to inflammatory stimuli (Fig. 3). Considering the physical location of the vestibular tissue and its unique embryonic origin, it makes sense that the vestibule serves as a protective barrier to vaginal infection, much like a moat around a castle (Chadha et al., 1998; Farage & Maibach, 2006; Friedrich Jr., 1983). This exaggerated response is deleterious and could explain the evolution of chronic pain, one of the cardinal symptoms of inflammation (dolor).

Knocking down or impairing the function of any one receptor reduces the response to inflammatory stimuli, but does not ablating this...
response (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018). Consistent with the literature, we determined activation of these receptors in turn triggers nuclear factor kappa B (NFκB) signaling in vulvar fibroblasts (Doyle & O’Neill, 2006; Gantner, Simmons, Canavera, Akira, & Underhill, 2003; Lawrence, 2009; Luqman & Pezzuto, 2010). Blocking NFκB activity using Bay-11–7082 ablates inflammatory mediatory production in vestibular fibroblasts, pointing to NFκB as a master regulator of inflammation in vulvodynia.

**Fig. 2.** LPV Model. 6 mm punch biopsies are collected during surgery from both LPV cases and from healthy controls (no vulvar disease). These are then sectioned into 3 pieces, each for a specific type of analysis, namely fibroblast isolation and culture, analysis of gene expression, and quantification of lipid profiles. An n of 1 represents 4 tissue samples, with only one painful sample from the vestibule of a case, while the remaining 3 samples, whether from case or control, are from non-painful areas of the vestibule and external vulva.

**Fig. 3.** Inflammatory Mechanisms of Vulvodynia. In patients with localized provoked vulvodynia, an aberration of a normally protective response against infection is exacerbarated by the elevated expression and function of nearly a dozen different receptors involved in innate immune responses (dectin-1, TLRs) and pain signaling (bradykinin receptors). This significantly increases levels of IL-6 and PGE2, which has been associated with pain in vulvodynia. On the left side, healthy controls are depicted, which express normal levels of receptors, responding only to infectious threats, which subsequently triggers immune clearance, after which inflammation resolves. On the right, LPV cases express abnormally high levels of receptors and respond to low numbers of organisms, even the resident flora. This triggers an abnormally strong response that does not resolve and leads to elevated inflammatory mediators associated with pain.
One potential barrier to the development of novel therapeutics is the need for preclinical models of disease. There are a few rodent models of vulvar pain that use allergens or irritants (e.g. hapten, oxazolone, streptozotocin, and methylisothiazolinone) to provoke vulvar sensitivity, but it is unclear if these exposures model any natural causes of vulvodynia (Akbar et al., 2016; Ali et al., 2015; Aman et al., 2016; Arriaga-Gomez et al., 2019; Awad-Igbaria et al., 2022; Boo et al., 2019; Pierce et al., 2015; Rangappa, Shankar, Jo, Repka, & Murthy, 2021). In a model developed by Farmer et al. mice were infected vulvovaginally with C. albicans or zymosan was injected into the midline vulvar skin immediately posterior to the vaginal opening (Farmer et al., 2011). Farmer determined vulvovaginal exposure to yeast or yeast products resulted in sustained allodynia, similar to what is observed in LPV patients. This is a key piece of evidence supporting the hypothesis that chronic yeast infection incites vulvar pain. However, the Farmer model was not designed to test therapeutic interventions. Therefore, we worked to expand the model to improve reproducibility, investigator comfort and reliability, and create a sustained window of stable allodynia (~16 weeks) for traditional pharmacokinetic testing (Falsetta et al., 2021).

The disease pattern in our model is similar to human allodynia; there is a clear inflammatory response during the induction phase in mice receiving zymosan injections (Falsetta et al., 2021). After the first few weeks, the response tapers off and there is no active inflammatory response at the time of treatment, while mice remain unreservedly sensitive to touch (<1 g force elicits a response). Congruent with the role of inflammation in LPV, we found that interrupting this process via twice daily topical application of the specialized pro-resolving mediator (SPM) maresin 1 increased sensitivity thresholds to pre-induction baselines in ~4 weeks, effectively alleviating pain. SPMs are small lipids involved in the resolution of inflammation. Unlike steroids or non-steroidal anti-inflammatory drugs (NSAIDs), SPMs do not risk compromising immune defense at a site that must respond to environmental threats (Serhan, 2017a; Serhan, Chiang, Dalli, & Levy, 2014). Rather, SPMs help to resolve inflammation faster and more efficiently, helping restore homeostasis, clear infection, and heal wounds (Buckley, Gilroy, & Serhan, 2014; Buckley, Gilroy, Serhan, Stockinger, & Tak, 2013; Chiruchhi et al., 2016; Cianci et al., 2016; Croasdell et al., 2015; Dakin et al., 2019; Fonseca, Orlando, Turchetti-Maia, & de Francisci, 2017; Levy & Serhan, 2014; Serhan, 2014; Serhan, 2017a; Serhan, 2017b; Serhan et al., 2014; Serhan, Chiang, & Dalli, 2015; Serhan, Chiang, & Dalli, 2018). There is a growing body of evidence to support their use as analgesic agents (Falsetta et al., 2021; Luo, Gu, Tao, Serhan, & Ji, 2019; Serhan et al., 2012; Tao, Lee, Donnelly, & Ji, 2020; Zhang et al., 2018). SPMs are naturally produced, safe, and do not result in dependence.

3. Lipid dysbiosis and vulvar pain

3.1. Why do the symptoms of vulvodynia persist?

For a long time, the resolution of inflammation was thought to be an inactive process mediated by a progressive tapering off of inflammatory signals as infection resolves and immune cells lyse and are no longer recruited to the site of infection (Buckley et al., 2014; Chiang & Serhan, 2017; Chiang & Serhan, 2020; Serhan, 2017a; Serhan, 2017b; Serhan et al., 2014; Serhan et al., 2015). However, with the discovery of SPMs, it became apparent that resolution is an active process governed by the secretion of lipid mediators that have specific and profound effects on immune cells that foster immune clearance and the return to homeostasis. The balance between resolution and inflammation has sometimes been referred to as a “Goldilocks mechanism” where everything needs to be “just right” to ensure resolution is sufficient but not overzealous. As discussed, in LPV, there is a heightened response to inflammatory stimuli in the vulvar vestibule, which represents an extreme of a naturally protective response (Fig. 3). However, this does not explain why resolution fails to quell this deleterious response nor how inflammation leads to vulvar allodynia.

The chronicity of inflammation led us to hypothesize that a defect in the resolution machinery could account for unresolved inflammation. Therefore, we elected to use targeted lipidomic analysis to quantify the abundance of lipids involved in both resolution and inflammation in vulvar tissues collected from LPV patients and healthy controls. Punch biopsies from painful sites in the vestibule and non-painful sites in the external vulva of LPV patients were analyzed along with matched biopsies from controls. One-third of each 6 mm biopsy was used for lipidomic analysis from a total of 10 case and 10 control patients. Three lipids implicated in resolution (12-hydroxyeicosatetraenoic acid (HETE), 8,9-eicosatrienoic acid (EET), and 14(15)-EET) were found to be highly and significantly reduced in the painful vestibule compared to non-painful areas from both cases and controls (Maddipati, 2020; Thomson, Askari, & Bishop-Bailey, 2012; Yu et al., 2000). We also observed concomitant increases in lipids involved in inflammation, such as PGE2. These findings indicated that there may be a deficit in the resolution machinery that accounts for the chronicity of inflammation. We therefore hypothesized that adding exogenous SPMs could overcome this deficit by compensating for the reduction in pro-resolving lipids. We elected to focus on SPMs, because our pilot experiments indicated they were reduced in vulvodynia patients, are already under development for human use, and likely effective at lower doses than their precursor lipids (e.g. 8(9)-EET).

3.2. Pro-resolving mediators reduce inflammation and vulvar pain

We used our fibroblast model to screen commercially available SPMs across a variety of dosages and dosing strategies in cells from both painful and non-painful areas (Falsetta et al., 2021). We first explored a pre-treatment model of vulvodynia, where we treated cells with the SPMs, then initiated inflammation using recombinant human interleukin-1β (IL-1β), an endogenous inflammatory stimulus, elicits a predictable and reproducible response, making it a useful tool for inducing inflammatory responses in human fibroblasts (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2021; Foster et al., 2015). Although, there are no laboratory tests for vulvodynia at present, it is our goal to identify an LPV lipid signature using targeted lipidomics. This signature could be used to screen asymptomatic patients and intervene before the onset of pain and comorbid conditions linked to pain. It could also be used as an objective clinical trial measure or clinical metric by which to assess the progression and remission of symptoms. Early screening and prevention could be used in patients with warning signs, such as a family history of vulvodynia or someone who is experiencing transient bouts of pain following intercourse. Vulvodynia may be heritable (Goldstein et al., 2014; Jeremias, Ledger, & Witrin, 2000; Kalton et al., 2019; Morgan et al., 2016; Reed, Harlow, Plegue, & Sen, 2015). This signature might also prove useful in establishing biological classifications of disease to help better define our current clinical classifications (e.g. provoked vs. unprovoked).

Using the prevention strategy, we were able to significantly attenuate the production of IL-6 and PGE2 in response to IL-1β for most, but not all SPMs (Falsetta et al., 2021). Resolvin D1, aspirin triggered resolvin D1, and the precursor of resolvin D1 (175-hydroxy docosahexaenoic acid, HDHA) were generally not successful in reducing mediator levels, while the others were highly effective in reducing IL-6.
and many also reduced PGE2. Therefore, we elected to try a treatment strategy, which is currently the most likely scenario as patients present with symptoms for a duration >3 months. Our results for the treatment strategy were comparable; most SPMs reduced IL-6 and several also reduced PGE2. This gave us a list of SPMs with greatest potential for reduction of inflammation in vulvodynia, which included maresin 1, lipoxin A4, and resolvin D2.

Before moving to testing analgesia in mice, we first determined that the mouse vulva both produces SPMs and expresses the majority of the G-coupled protein receptors (GPCRs) that recognize various SPMs. We also determined that explants of mouse vulvar tissue cultured as 3D tissue biopsies were highly responsive to maresin 1, lipoxin A4, and resolvin D2, demonstrated through their ability to reduce PGE2 (Falsetta et al., 2021). Of the three, maresin 1 reduced PGE2 to the greatest magnitude, placing maresin 1 as a front runner for future drug development.

We went on to test the analgesic effects of maresin 1 and docosahexanoic acid (DHA) in our mouse model of vulvodynia (Falsetta et al., 2021). DHA, a dietary polyunsaturated fatty acid, is a precursor for maresin synthesis. Maresin 1 was highly effective in returning sensitivity thresholds to their starting baselines. In models of tactile or mechanical allodynia, a von Frey probe is used to measure the tolerance to pressure, as is done clinically to determine thresholds in humans. The greater the force withheld without withdrawal, the lower the sensitivity. Mice with high sensitivity will react and withdraw or evade the probe with little to no force applied. Mice receiving maresin 1 recovered to and exceeded their starting baseline after 4 weeks of twice-daily treatment weekdays and once-daily treatment on weekends. Mice receiving vehicle also recovered during this period, but not to the magnitude of those receiving maresin 1 and did not exceed baseline. Mice that did not develop allodynia that received maresin 1 showed no significant difference in their thresholds compared to baseline. The vehicle contained dimethyl sulfoxide (DMSO), which has analgesic properties on its own (Morris, 1966). Although this may not be ideal for detecting differences in a laboratory experiment, any benefit added by the vehicle would be welcome in a clinical application. This data demonstrated that SPMs have a high potential for therapeutic translation in humans; clinical trials will be necessary to move forward. Currently, it is unclear whether chronic SPM treatment would be needed to maintain its effects in humans. Mice recover completely after a short duration of treatment, but this remains to be tested in vulvodynia patients. Although SPMs represent a promising avenue for therapeutic development, this did not explain the cause for this deficit, nor how inflammation might elicit pain in the vulva.

4. Neuro-inflammatory mechanisms of vulvar pain

4.1. Pools of lipids involved in pain signaling are sustained in the painful vestibule

In exploring the mechanisms responsible for deficiencies in pro-resolving lipids using a targeted lipidomic analysis panel comprised of ~150 pro-resolving and inflammatory mediators, we made an unexpected finding. There are 4 EETs that are implicated in resolution: 5(6)-EET, 8(9)-EET, 11(12)-EET, and 14(15)-EET (Thomson et al., 2012; Yu et al., 2000). Since half of these were significantly less abundant in the painful vestibule, we became interested in their metabolism. EETs are produced by members of the cytochrome peroxidase (CYP) 450 family from the polyunsaturated dietary fatty acid arachidonic acid (Hammock et al., 2021; Pearson, Warren, Barrett, & Khan, 2009). EETs can be broken down to their less active, but not completely inactive dihydroxyeicosatrienoic acid (DHET) forms by an enzyme known as soluble epoxide hydrolase (sEH) (Hammock et al., 2021; Pearson et al., 2009; Thomson et al., 2012; Yu et al., 2000). Previous studies have shown that inhibiting sEH can have pro-resolving and even analgesic properties by reducing EET degradation and thus maintaining EET pools (Hammock et al., 2021; Thomson et al., 2012; Yu et al., 2000). Therefore, we wanted to determine if EET levels were reduced in the painful vestibule because of enhanced sEH degradation or reduced production by CYP450. Our lipidomic analysis also measured DHETs, which allowed us to calculate a ratio of active EET over inactive DHET for each of the 4 EETs. We anticipated a decrease in this ratio for at least 8(9)-EET and 14(15)-EET based on their reduced abundance in the painful vestibule. However, only one EET ratio showed a significant difference, which was 5(6)-EET. Surprisingly, 5(6)-EET active pools were enhanced in the painful vestibule, which appeared to be the result of a reduction in the 5(6)-DHET breakdown product. However, our lipidomic screen does not measure other metabolites of 5(6)-EET, and sustained DHETs levels do not preclude the involvement of sEH.

5(6)-EET is exceedingly short-lived and difficult to measure (Zosmer, Elder, & Sullivan, 2002). Therefore, its sustained presence in the painful vestibule was noteworthy. Although there is empirical evidence for the role of 8(9)-EET, 11(12)-EET, and 14(15)-EET in resolution (Thomson et al., 2012; Yu et al., 2000), there are no publications that demonstrate such a role for 5(6)-EET. The most established role for 5(6)-EET is activation of the transient receptor potential vanilloid subtype 4 receptor implicated in pain signaling, specifically mechanical allodynia (Berna-Erro et al., 2017). Although inflammation is related to pain, this was the first evidence for enhanced pain signaling in the vestibule of LPV patients suggestive of a neuro-inflammatory mechanism. However, the relationship between inflammation, lipids, and TRPV4 signaling would prove to be even more complex than we initially hypothesized.

4.2. TRPV4 signaling is elevated in painful areas and fed by inflammation

We next determined that 1) TRPV4 is more highly expressed in the painful vestibule, and 2) knocking it down reduces inflammatory mediator production in vulvar fibroblasts. Heightened receptor expression (TRPV4) combined with heightened levels of the receptor ligand (5(6)-EET) could lead to enhanced pain signaling. However, the relationship with inflammation was less clear. We hypothesized that activation of TRPV4 would foster increases in PGE2 and IL-6, which is consistent with the literature. TRPV4 activation often increases inflammatory mediator production through activation of downstream inflammatory pathways (Ito et al., 2017; Kaneko & Sallasi, 2014; Mickle, Shepherd, & Mohapatra, 2015; Moore, Gupta, Jorjd, Chen, & Liedtke, 2018; Moran & Sallasi, 2018; Poole et al., 2013; Wang et al., 2011). Therefore, we challenged vulvar fibroblasts with increasing concentrations of the TRPV4 synthetic activator 4alpha-Phorbol 12,13-didecanoate (4alphaPDD) expecting to see concomitant increases in PGE2 and IL-6. However, even the highest doses of 4alphaPDD, which showed some cellular toxicity, did not increase levels over the vehicle control. This was surprising, but it fit with other observations that 4alphaPDD was unable to activate calcium flux in fibroblasts, while they were responsive to the positive controls adenosine diphosphate (ADP) and histamine. TRPV4 is a non-specific cation channel that is permeable to calcium (Darby, Grace, Baratchi, & McIntyre, 2016; Vriens et al., 2005). Measuring intracellular calcium is a convenient and sensitive measurement of calcium flux through the channel.

In taking a step back, we realized that we were missing a key element necessary to best model vulvodynia, which was ongoing inflammation. In vulvodynia, patients appear to have chronic, low levels of inflammation that likely play a role in pain. Therefore, we pre-treated cells with IL-1β overnight before challenging with 4alphaPDD for our calcium flux experiments. We found that with IL-1β pre-treatment, cells responded to 4alphaPDD, even at the lowest dose. When we simultaneously treated cells with IL-1β and increasing doses of 4alphaPDD, we saw a dramatic increase in IL-6 and PGE2 levels, which were up to 5-fold higher than in cells treated with IL-1β alone. Altogether these results indicate concomitant inflammation is required for TRPV4 signaling to proceed in vulvar fibroblasts. Because levels of IL-6 and PGE2 could be reduced
with an inhibitor of TRPV4 (HC064047) without any added 4αPDD, we wondered if inflammation alone was sufficient to initiate calcium signaling. We found that IL-1β (endogenous stimulus) and Poly(I:C), an exogenous stimulus that mimics viral RNA, could initiate calcium flux without an activator of TRPV4, indicating inflammation is both necessary and sufficient for TRPV4 signaling. In addition, we determined that TRPV4 activity is highest in the painful vestibule in response to 4αPDD, Poly(I:C), and the natural activator, 5(6)-EET, suggesting that changes in lipid profiles in the vulvar vestibule play a role in disease.

4.3. Inflammation induces changes in lipid profiles fostering inflammation and TRPV4 signaling

To investigate how inflammation influences the vulvar lipidome, we treated fibroblasts with IL-1β, Poly(I:C), or vehicle. We found that lipids involved in the resolution of inflammation (e.g., lipoxin B₄, maresin 1, EETs) were significantly reduced in the painful vestibule of cells treated with endogenous or exogenous inflammatory stimuli. At the same time, lipids involved in inflammation (e.g. prostaglandins, leukotrienes) increased with inflammatory stimulation. The greatest degree of change occurred with Poly(I:C) treatment, suggesting that cells are more responsive to exogenous stimuli, consistent with the idea that chronic vulvovaginal infection precipitates vulvodynia symptoms. Poly(I:C) stimulates toll-like receptor 3 (TLR-3), which is more highly expressed in the painful vestibule and is involved in the recognition of nucleic acids from various microorganisms (Chiba et al., 2013; Falsetta et al., 2018). As discussed earlier, yeast infections have been implicated in the onset of vulvodynia, although most yeast infections are not diagnosed clinically. The TLR receptors, which are involved in the inflammatory response in vulvodynia, recognize yeast cells and their products, but they also recognize bacteria and viruses (Bourgeois & Kuchler, 2012; Doyle & O’Neill, 2006; Falsetta et al., 2018; Gow et al., 2012). Therefore, it is unclear if yeast species are the causative agent or whether there are other triggers. This is an area of current investigation. Nonetheless, inflammatory stimuli clearly alter lipid profiles in the painful vestibule, which favors inflammation and TRPV4 pain signaling, while reducing the resolution capacity, as evidenced by reductions in pro-resolving lipids in vestibular tissue and fibroblasts.

The combination of heightened inflammatory responses to even the resident microbiota and a defect in the ability to quell this response, which is linked pain signaling, represents the “perfect storm,” eliciting chronic low levels of inflammation and pain in LPV patients. Targeting TRPV4 with HC067047 reduces inflammatory signaling, suggesting targeting TRPV4 could be another option for therapeutic development.

4.4. Treatment strategies structured around the known vulvodynia mechanism

Reducing inflammation and enhancing resolution through the application of SPMs and their precursors appears to be a viable treatment strategy for vulvodynia, especially given the profound analgesic properties of maresin 1 and DHA (Falsetta et al., 2021). We have also explored the use of fish oils that are naturally enhanced for DHA and intermediates of SPM synthesis, such as 14-HDHA. These too are highly effective in reducing signs of pain in mice with vulvar allodynia. Whether this will translate to significant effects in humans remains to be seen. However, there is good reason to believe translation is likely. The use of a natural product could lead to faster implementation; SPMs cannot be purified in sufficient quantities from dietary sources, warranting chemical synthesis and FDA-regulated drug development steps.

In exploring the TRPV4 pathway, we became curious as to whether maresin 1 would impact TRPV4 signaling; SPMs, especially resolvins, have been shown to reduce the activity of closely related TRPV1 (Bang et al., 2010; Bang, Yoo, Yang, Cho, & Hwang, 2012; Jo, Lee, & Park, 2016; Luo et al., 2019; Park et al., 2011; Payrits et al., 2020; Serhan et al., 2012). TRPV1 recognizes capsaicin, the spicy component in chili peppers, and has been implicated in peripheral neuropathy pain (Kaneko & Szallasi, 2014; Mickle et al., 2015; Moore et al., 2018; Moran & Szallasi, 2018). We found that maresin 1 was able to impede TRPV4 signaling on the order of seconds, demonstrating an acute effect. This helps to explain maresin’s impressive pain-reducing capacity in our mouse model; it can quell the inflammation that is necessary to elicit TRPV4 signaling and it can act on TRPV4 acutely. Maresin 1, and possibly other SPMs, act on multiple parts of the established LPV mechanism. We...
have found that inflammatory signaling helps to increase the expression of TRPV4, while TRPV4 activation results in the augmentation of inflammatory signaling. This represents a feed-forward loop causing amplification of the signals involved in inflammation and pain signaling, much like a snowball rolling down a hill. Maresin 1 is able to reduce the size of the snowball by both quelling inflammation and inhibiting TRPV4 signaling (Fig. 4).

Although, we have thus far only scratched the surface of the LPV mechanism, we have identified a class of molecules with high therapeutic capacity, which offer almost no toxicity as they are naturally produced or based on naturally produced molecules. As we continue to investigate the mechanism, we are likely to identify other analgesic targets. However, SPMs may show superior pain-relieving capacity as they act on more than one part of the pathway. We have identified other therapeutic options that could involve the use of off-label therapies such as antifungals, which also target CYP450 (Kjaerstad et al., 2010) and may reduce 5(6)-EET levels, or NSAIDs that target cyclooxygenase-2 (COX-2) and thus the production of PGE₂ (Kawabata, 2011). Even diet modification to reduce sources of arachidonic acid synthesis could be another possibility, especially given that there is some evidence for the benefits of a low oxalate diet in vulvodynia, which is naturally low in sources of linoleic acid, from which arachidonic acid is produced (Greenstein et al., 2006; Harlow, Abenhaim, Vitonis, & Hanack, 2008). Improved understanding of the biological mechanisms that precipitate and sustain vulvodynia symptoms will only serve to enhance the odds of identifying promising new therapeutic avenues.

5. Conclusion

There is considerable work to be done, but SPMs show promise for the development of new therapeutics for LPV. They are safe and naturally produced, although drug development steps are necessary for chemically synthesized SPMs. Natural products, such as purified fish oil could represent another option, although this may not be as potent as SPMs, especially considering the apparent dysregulation of lipid metabolism in LPV patients. Natural products also pose other challenges for drug development, because they may not be patentable products. LPV appears to arise from an extreme of a normal process that provides immune defense to limit vaginal infection (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018; Falsetta et al., 2021; Foster et al., 2015). However, in patients, whether from environmental exposure, genetics, or a combination of these, a “perfect storm” occurs, where patients have enhanced inflammation without the ability to fully resolve this inflammation. This in turn leads to changes in lipid profiles and ultimately the activation of pain signaling pathways.

Fibroblasts are not sensory cells, but they may act as feeder cells to amplify inflammation and pain signals; PGE₂ sensitizes neurons (Reinold et al., 2005; Shapiro, Singh, & Ariel, 2016). Enhanced understanding of the LPV mechanism has uncovered new therapeutic targets and may help to diagnose and assess patients at earlier disease states to limit comorbid conditions and distress. Inflammation may be local in vulvodynia, but even local inflammation has systemic effects, altering brain chemistry and inducing sickness behaviors (Elenkov, Iezzoni, Daly, Harris, & Chrousos, 2005; Elmqist, Scammell, & Saper, 1997; Knor et al., 2010; Pentreath, Baugh, & Lavin, 1994; Perry, 2004; Perry, 2010; Zhang et al., 2008). Inflammation is a key trigger that initially pushes the snowball down the hill. We have identified several possibilities to prevent or limit inflammation and thus the size of the snowball or prevent its formation entirely. The logical next step is to implement this knowledge clinically through FDA-approved trials, while continuing our investigations of the vulvodynia mechanism.

6. Current knowledge gaps and future directions

Although our mouse model of vulvodynia mimics the human disease in several key ways, it is impossible to recapitulate every aspect of human disease in an animal model, especially when the mechanisms of that disease are not yet fully elucidated. There is strong suspicion that vulvodynia is genetically inherited; a vulvodynia diagnosis is more likely if you have a first degree relative with this disease (Morgan et al., 2016). The data we have collected thus far points to a deficit in the metabolism of AA that favors inflammation while resolution is diminished. There are several well-defined small nucleotide polymorphisms (SNPs) associated with neuropathic pain that occur in the lipooxygenase genes, a key family of enzymes that metabolize AA (Zheng et al., 2020). One of our key future directions is to conduct genomic sequencing to identify potential SNPs or genetic changes that could explain the observed metabolic changes. This could lead to discovery of new screening tools for vulvodynia, help us to better understand the mechanism of disease, and give us additional parameters we can model in mice to more faithfully recapitulate human vulvodynia.

In addition to furthering our mechanistic understanding of disease, we plan to trial topical SPM therapy in vulvodynia patients. The University of Rochester was issued US patent 11,400,057 “Treatment of Vulvar Pain” for exclusive topical use of SPMs and similar preparations (e.g. fish oil) in vulvodynia patients. We are in the process of planning an industry-sponsored FDA phase I/II trial using SPMs exclusively licensed to the sponsor. We anticipate that SPM therapy will improve patient reported outcomes, but there are several steps to complete, including formulation, stability programs, safety, and efficacy testing. Unfortunately, only 11% of successful animal trials translate to FDA approved applications in humans (Mogil, 2009). Therefore, while we move towards a clinical trial, we are continuing our mechanistic investigations to leave the door open for other therapeutic options and diagnostic strategies. There is still no objective test to diagnose vulvodynia, which is a significant reason many patients suffer for years before they are diagnosed and treated (Haefner et al., 2005; Stockdale & Lawson, 2014).

Declaration of Competing Interest

We do not have any conflicts of interest to disclose.

Acknowledgments

We have no conflicts to disclose. This work was funded by NIH-NICHD R01 HD092334 and R01 HD069313 and the National Vulvodynia Association. All figures were created with BioRender.com.

References


M.L. Falsetta, K.R. Maddipati and K.V. Honn

Pharmacology & Therapeutics 248 (2023) 108467

following chronic compression of the dorsal root ganglion in rats. 

science. Pain. https://doi.org/10.1016/j.pain.2014.05.010 1016/j.pain.2014.05.010

Zosmer, A., Elder, M. G., & Sullivan, M. H. (2002). The production of progesterone and 5,6-
epoxyeicosatrienoic acid by human granulosa cells. Pharmacotherapy 129

Wu, C., Goldstein, A., Klebanoff, J. S., & Moawad, G. N. (2019). Surgical management of

https://doi.org/10.1111/1471-0528.14415. 27860096.


Zosmer, A., Elder, M. G., & Sullivan, M. H. (2002). The production of progesterone and 5,6-